Global pharmaceutical company Pfizer (NYSE: PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.

Is now the time to buy Pfizer? Find out by accessing our full research report, it’s free.

Company Overview

With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE: PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Unfortunately, Pfizer’s 2.1% annualized revenue growth over the last five years was tepid. This wasn’t a great result, but there are still things to like about Pfizer.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Pfizer’s annualized revenue growth of 6.4% over the last two years is above its five-year trend, which is encouraging.

We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Pfizer’s organic revenue averaged 7.8% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results.

This quarter, Pfizer reported modest year-on-year revenue growth of 2.6% but beat Wall Street’s estimates by 4.4%.

Looking ahead, sell-side analysts expect revenue to decline by 3.9% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and implies its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.

Pfizer has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 31.2%.

Analyzing the trend in its profitability, Pfizer’s adjusted operating margin decreased by 11.4 percentage points over the last five years, but it rose by 9.8 percentage points on a two-year basis. Still, shareholders will want to see Pfizer become more profitable in the future.

In Q2, Pfizer generated an adjusted operating margin profit margin of negative 1.6%, down 37.9 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Pfizer’s flat EPS over the last five years was below its 2.1% annualized revenue growth. This tells us the company became less profitable on a per-share basis as it expanded.

We can take a deeper look into Pfizer’s earnings to better understand the drivers of its performance. As we mentioned earlier, Pfizer’s adjusted operating margin declined by 11.4 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, Pfizer reported adjusted EPS of $0.77, down from $0.78 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Pfizer’s full-year EPS to shrink by 9.1% from $3.05 to $2.77.

Key Takeaways from Pfizer’s Q2 Results

We enjoyed seeing Pfizer beat analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its full-year EPS guidance missed and its full-year revenue guidance was in line with Wall Street’s estimates. Overall, this print was mixed but still had some key positives. The stock remained flat at $25.16 immediately after reporting.

Big picture, is Pfizer a buy here and now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).